Clinical Study Using Antiaging Glycopeptide (PKX-001) in Islet Transplantation
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2017
At a glance
- Drugs PKX 001 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man
- 09 Mar 2017 According to a Protokinetix media release, the fist patient has been treated in this trial.
- 02 Mar 2017 Status changed to recruiting.
- 17 Jan 2017 According to a ProtoKinetix media release, the Governors of the University of Alberta have submitted an investigational testing authorization application to commence clinical studies in Canada. This authorization will allow the clinical trial group to enroll Canadian patients into the study.